HOME >> MEDICINE >> NEWS
Higher doses of cancer drug imatinib proven effective and safe

ortance as previous studies of another cancer drug (interferon alpha) have shown that CCR is associated with a 70 to 80 percent chance of 10-year survival, a positive prospect as the survival time for newly diagnosed CML patients is typically about five years.

Another measure of successful treatment is the number of patients with complete molecular response, occurring when the levels of BCR-ABL are so low that they are undetectable using a highly sensitive method called polymerase chain reaction. In past studies, patients who had undetectable levels of BCR-ABL after treatment have not relapsed after long-term follow up. In high-dose therapy patients, the incidence of complete molecular response was 28 percent compared to only seven percent of patients taking the standard dosage of imatinib.

"The high rates of complete cytogenetic and molecular response that we've seen in this study are unprecedented. If such responses have similar long-term significance as seen in previous studies, this translates into a major improvement in the prognosis of patients with CML," states Hagop Kantarjian, M.D., chairman of the Department of Leukemia at M. D. Anderson Cancer Center and the lead author of the study.

Researchers found that the high dosage of imatinib was generally well tolerated, with a similar rate of side effects as standard dose imatinib. To reduce more severe side effects, the dosage of imatinib was lowered to 600 mg or 400 mg daily for some patients, though a majority remained at the target dosage.

The disease did not transform beyond the chronic phrase in any of the study patients, and 98 percent had a complete hematologic response, meaning the number of white blood cells was no longer out of control and the signs and symptoms of leukemia were gone.

The results of the study indicate that patients in the early stage of this cancer may benefit from higher doses of the drug imatinib in their initial treatment to safely and effe
'"/>

Contact: Aislinn Raedy
araedy@hematology.org
202-776-0544
American Society of Hematology
1-Apr-2004


Page: 1 2 3

Related medicine news :

1. Higher folate intake associated with decreased risk of hypertension in women
2. Higher incidence of rejection following early steroid withdrawal
3. Higher radiation doses help some lung cancer patients live longer
4. Higher dose of Gleevec leads to increased remission in CML patients
5. Higher education or larger brain size may protect against dementia later in life, new study finds
6. Higher cost sharing reduces plans drug expenditures, but boosts enrollee costs
7. Higher nocturnal blood pressure predictive of kidney disease in diabetes
8. First quarter 2002 prescription drug spending: Higher again, but rate of increase drops
9. Higher rate of improvement, lower rate of adverse effects with clarithromycin for acute exacerbations of chronic bronchitis
10. Cancer Rates In Children Of Nuclear Industry Employees No Higher Than General Population In England And Wales
11. New Study Finds Blacks Face 38 Percent Higher Stroke Risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Higher doses cancer drug imatinib proven effective and safe

(Date:8/31/2015)... ... ... MeYou Health ®, a social well-being company and wholly owned subsidiary of Healthways, ... in-app step tracker. , Walkadoo is a pedometer-based walking program that provides ... every Walkadoo member 10,000 steps a day (as is typical for many walking programs), ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s big news for ... digital healthcare industry. , Consumer driven health plans (CDHPs) are a growing phenomenon, ... and strategic role to the company, and another to answer customers’ questions directly. , ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Brooks Group, a ... , a department devoted to helping organizations identify and keep the best talent ... and The Brooks Group believes in offering a solution that goes beyond simply ...
(Date:8/31/2015)... ... ... Now here’s some good health news: Nearly two-thirds of Americans say they ... with the majority of Americans eating more whole grains than they did five years ... findings and others from the 2015 Whole Grains Consumer Insights Survey in time for ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now through October 31st, ... will be featured on a digital screen projected above New York’s Times Square, ... and promote earlier awareness of the symptoms of ovarian cancer, and earlier conversations ...
Breaking Medicine News(10 mins):Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
Cached News: